VSTM logo

VSTM
Verastem Inc

24,046
Mkt Cap
$465.53M
Volume
2.93M
52W High
$11.25
52W Low
$4.01
PE Ratio
-1.67
VSTM Fundamentals
Price
$5.55
Prev Close
$5.30
Open
$5.41
50D MA
$5.93
Beta
1.33
Avg. Volume
2.26M
EPS (Annual)
-$3.02
P/B
7.54
Rev/Employee
$303,078.43
$417.24
Loading...
Loading...
News
all
press releases
Verastem's (VSTM) "Buy" Rating Reaffirmed at Jefferies Financial Group
Jefferies Financial Group reissued a "buy" rating and issued a $15.00 target price (down from $19.00) on shares of Verastem in a research note on Monday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Analysts
Shares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have been assigned a consensus rating of "Buy" from the ten research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five h...
MarketBeat·3d ago
News Placeholder
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
Zacks·6d ago
News Placeholder
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been...
Business Wire·15d ago
News Placeholder
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Womens Cancers
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term...
Business Wire·15d ago
News Placeholder
Foresite Capital Management VI LLC Has $23.09 Million Holdings in Verastem, Inc. $VSTM
Foresite Capital Management VI LLC increased its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 104.9% during the third quarter, according to its most recent Form 13F filing with...
MarketBeat·17d ago
News Placeholder
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research
BTIG Research reissued a "buy" rating and set a $19.00 target price on shares of Verastem in a research note on Thursday...
MarketBeat·21d ago
News Placeholder
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
The mean of analysts' price targets for Verastem (VSTM) points to a 159.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·21d ago
News Placeholder
Jefferies Financial Group Inc. Increases Stake in Verastem, Inc. $VSTM
Jefferies Financial Group Inc. increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 48.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange...
MarketBeat·23d ago
News Placeholder
Verastem (NASDAQ:VSTM) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded Verastem from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·26d ago
<
1
2
...
>

Latest VSTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.